Urinary leukotriene E4 in the assessment of nocturnal asthma. 1996

V Bellia, and A Bonanno, and F Cibella, and G Cuttitta, and A Mirabella, and M Profita, and A M Vignola, and G Bonsignore
Istituto di Medicina Generale e Pneumologia-Universit¿a, Palermo, Italy.

BACKGROUND Urinary leukotriene E4 (LTE4) is a marker of the body's production of cysteinyl LTs, important mediators of airway inflammation. The role of the latter in nocturnal asthma is a topic of increasing interest. OBJECTIVE This investigation was aimed at determining whether nighttime attacks are associated with increased release of LTs, expressed by urinary LTE4, and the relationship between the two phenomena. METHODS Three groups were studied: group A, seven control subjects; group B, nine asthmatic patients without nocturnal attacks; and group C, nine asthmatic patients with a comparable daytime FEV1 but who were experiencing nocturnal exacerbations (morning dips in peak expiratory flow greater than 20%). Urine was collected over 24 hours in three samples (9:00 AM to 3:00 PM; 3:00 PM to 9:00 PM; and 9:00 PM to 9:00 AM). LTE4 was measured by high-performance liquid chromatography and radioimmunoassay and expressed as nanograms per millimole of creatinine. RESULTS No significant differences between urinary LTE4 were noticed within groups A and B. Conversely, in group C urinary LTE4 at night (geometric mean with 95% confidence interval; 35.16 with 28.77-42.85) was significantly higher than that of the other samples (respectively 23.12 with 17.78-30.06, p less than 0.05; and 25.18 with 21.03-30.13, p less than 0.02); it was also significantly higher than in all the samples of other groups. A significant (p less than 0.02) linear correlation was observed between morning dip in peak expiratory flow and the log urinary LTE4 in the nocturnal sample. CONCLUSIONS These results indicate the role of LTs in nocturnal asthma and suggest that urinary LTE4 may be a useful marker of this condition.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000204 Activity Cycles Bouts of physical irritability or movement alternating with periods of quiescence. It includes biochemical activity and hormonal activity which may be cellular. These cycles are shorter than 24 hours and include sleep-wakefulness cycles and the periodic activation of the digestive system. Activity Cycle,Cycle, Activity,Cycles, Activity
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D017999 Leukotriene E4 A biologically active principle of SRS-A that is formed from LEUKOTRIENE D4 via a peptidase reaction that removes the glycine residue. The biological actions of LTE4 are similar to LTC4 and LTD4. (From Dictionary of Prostaglandins and Related Compounds, 1990) LTE4,Leukotriene E,Leukotriene E-4,Leukotrienes E,Leukotriene E 4

Related Publications

V Bellia, and A Bonanno, and F Cibella, and G Cuttitta, and A Mirabella, and M Profita, and A M Vignola, and G Bonsignore
June 1992, The European respiratory journal,
V Bellia, and A Bonanno, and F Cibella, and G Cuttitta, and A Mirabella, and M Profita, and A M Vignola, and G Bonsignore
August 1992, Journal of applied physiology (Bethesda, Md. : 1985),
V Bellia, and A Bonanno, and F Cibella, and G Cuttitta, and A Mirabella, and M Profita, and A M Vignola, and G Bonsignore
January 2002, Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993),
V Bellia, and A Bonanno, and F Cibella, and G Cuttitta, and A Mirabella, and M Profita, and A M Vignola, and G Bonsignore
November 2007, Immunology and allergy clinics of North America,
V Bellia, and A Bonanno, and F Cibella, and G Cuttitta, and A Mirabella, and M Profita, and A M Vignola, and G Bonsignore
June 1992, The Journal of allergy and clinical immunology,
V Bellia, and A Bonanno, and F Cibella, and G Cuttitta, and A Mirabella, and M Profita, and A M Vignola, and G Bonsignore
January 2014, International journal of general medicine,
V Bellia, and A Bonanno, and F Cibella, and G Cuttitta, and A Mirabella, and M Profita, and A M Vignola, and G Bonsignore
October 1996, Arerugi = [Allergy],
V Bellia, and A Bonanno, and F Cibella, and G Cuttitta, and A Mirabella, and M Profita, and A M Vignola, and G Bonsignore
May 1991, Pediatric research,
V Bellia, and A Bonanno, and F Cibella, and G Cuttitta, and A Mirabella, and M Profita, and A M Vignola, and G Bonsignore
December 1991, The American review of respiratory disease,
V Bellia, and A Bonanno, and F Cibella, and G Cuttitta, and A Mirabella, and M Profita, and A M Vignola, and G Bonsignore
November 2003, Chest,
Copied contents to your clipboard!